Ian Taylor, Ph.D., serves as the Chief Scientific Officer at ARVINAS INC, a position he has held since joining the company in 2018. Dr. Taylor is a distinguished biochemist and molecular biologist with extensive experience in drug discovery and development. Prior to his role at ARVINAS, he held significant positions at major pharmaceutical companies, including Merck & Co., where he led research teams focused on developing novel therapeutics for cancer and other diseases. His academic journey began at the University of Cambridge, where he earned his Ph.D. in Biochemistry, followed by postdoctoral research at the Massachusetts Institute of Technology (MIT). At ARVINAS, Dr. Taylor has been instrumental in advancing the company's mission to develop groundbreaking therapies using its proprietary PROTAC® (PROteolysis TArgeting Chimera) technology. Under his leadership, ARVINAS has made significant strides in its clinical pipeline, with several programs now in advanced stages of development for treating various cancers and neurodegenerative diseases. His strategic vision and scientific expertise have been pivotal in securing key partnerships and collaborations with leading pharmaceutical companies, which have bolstered ARVINAS's research efforts and expanded its reach in the biopharmaceutical industry. Dr. Taylor's contributions to the field of targeted protein degradation have been widely recognized, with numerous publications in high-impact scientific journals and several patents to his name. His work not only exemplifies innovation in drug discovery but also underscores his commitment to translating scientific discoveries into tangible benefits for patients. As Chief Scientific Officer, Dr. Taylor continues to drive ARVINAS's scientific strategy, fostering a culture of excellence and collaboration that positions the company at the forefront of the next generation of therapeutics.